— Randomized, placebo-controlled, Phase 2a trial demonstrated robust, statistically significant antidepressant effects of ALTO-207 and favorable tolerability; supporting development of ALTO-207 in ~7...
— Phase 2b closely resembles PAX-D study design, which demonstrated an effect size for pramipexole more than two times larger than approved TRD therapies — — Trial...
The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up +0.11%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.11%. June E-mini...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.06%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.20%. June E-mini S&P futures...
The S&P 500 Index ($SPX ) (SPY ) today is down -1.13%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -1.15%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.53%. June E-mini S&P futures...
— In the proof-of-concept study, ALTO-101 did not achieve statistical significance on primary endpoint; signals observed across EEG measures including near-significant improvement in theta-ITC (p=0.052)...
– Financing led by Commodore Capital with participation from new and existing biotech focused investors – – Alto expects to use the proceeds of the financing to...
– Acquisition of ALTO-207 targets Treatment-Resistant Depression (TRD) with a clinically-validated mechanism; Phase 2b trial on track to be initiated in the first half of 2026 – ...
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...